Methods and compositions for preparing transplant tissue
Methods and compositions for preparing and priming a tissue graft for an accelerated therapeutic effect are provided herein. In one embodiment, the method includes obtaining a tissue containing viable cells from a donor, wherein the viable cells are endogenous to the tissue and remain resident in the tissue; and priming the viable cells with one or more stimuli comprising simulated hypoxia to produce a primed tissue, wherein when grafted to a recipient the primed tissue provides a benefit compared to non-primed tissue.
1. A method for providing an artificially primed tissue graft, comprising:
obtaining a tissue containing viable cells from a donor, wherein the viable cells are endogenous to the tissue and remain resident in the tissue;
priming the viable cells with one or more stimuli comprising simulated hypoxia to produce the artificially primed tissue graft which comprises an increased amount of angiogenic growth factors compared to a non-primed tissue, wherein when used to treat a patient the artificially primed tissue graft provides a benefit compared to non-primed tissue; and
decellularizing the primed tissue graft prior to grafting.
2. The method of claim 1 , wherein the tissue is obtained from one or more of placenta, amnion, chorion, umbilical cord, Wharton's Jelly, bone, periosteum, cartilage, meniscus, spinal disc, muscle, tendon, ligament, adipose, skin, cardiovascular tissue, peritoneum, fascia, nerve, cornea, visceral organ, reproductive tissue, hair follicles, foreskin, and dental tissue.
3. The method of claim 1 , wherein the simulated hypoxia is induced by exposing the tissue and resident endogenous viable cells to a medium ingredient that simulates hypoxia.
4. The method of claim 3 , wherein the medium ingredient comprises deferoxamine.
5. The method of claim 1 , wherein the benefit comprises one or more of (1) altered cell adhesion, altered cell proliferation, altered cell survival, maintenance of cell viability, maintenance of cell phenotype and/or altered cell migration; (2) induced cell differentiation, de-differentiation and/or transdifferentiation; (3) production of extracellular matrix and/or biochemical factors; (4) faster or improved healing or remodeling; (5) reduced risk of infection; (6) reduced risk of graft rejection; and (7) reduced level of inflammation.
6. The method of claim 1 , wherein the benefit is the an increased amount of angiogenic growth factors and wherein the angiogenic growth factors comprise one or more of: epidermal growth factor (EGF), hepatocyte growth factor (HGF), and placental growth factor (PGF).